Definium Therapeutics (DFTX) Gains from Investment Securities (2021 - 2026)
Definium Therapeutics (DFTX) reported Gains from Investment Securities of -$118000.0 for Q1 2026, down 1280.0% year-over-year from $10000.0 in Q1 2025, and down 594.12% quarter-over-quarter from -$17000.0 in Q4 2025.
Definium Therapeutics (DFTX) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 6 years of Gains from Investment Securities data on file, last reported at -$118000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$118000.0, down 1280.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.6 million (up 175.05% YoY), and the FY2025 annual result was -$30000.0, down 155.56% from the prior year.
- Gains from Investment Securities fell to -$118000.0 in Q1 2026 per DFTX's latest filing, from -$17000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $32.9 million in Q1 2024 and troughed at -$13.4 million in Q2 2024.
- A 5-year average of $1.0 million and a median of -$17000.0 in 2025 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 182838.89% in 2024 and fell as far as 18490.0% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$8.2 million in 2022, then surged by 100.73% to $60000.0 in 2023, then sank by 18490.0% to -$11.0 million in 2024, then soared by 99.85% to -$17000.0 in 2025, then slumped by 594.12% to -$118000.0 in 2026.
- Business Quant data shows DFTX's Gains from Investment Securities at -$118000.0 in Q1 2026, -$17000.0 in Q4 2025, and $22.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -118,000.00 |
| Mar 31, 2026 | -118,000.00 |
| Dec 31, 2025 | -17,000.00 |
| Dec 31, 2025 | -17,000.00 |
| Sep 30, 2025 | 22.55 Mn |
| Sep 30, 2025 | 22.55 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | -11.03 Mn |
| Dec 31, 2024 | -11.03 Mn |
| Sep 30, 2024 | -8.36 Mn |
| Sep 30, 2024 | -8.36 Mn |
| Jun 30, 2024 | -13.45 Mn |
| Jun 30, 2024 | -13.45 Mn |
| Mar 31, 2024 | 32.89 Mn |
| Mar 31, 2024 | 32.89 Mn |
| Dec 31, 2023 | 60,000.00 |
| Dec 31, 2023 | 60,000.00 |